Cell>Point has entered into long-term commitments to financially sponsor and support continuing research and development at M. D. Anderson Cancer Center for the EC Technology, In-Situ Hydrogel, N4 Technology, Dual Agent Technology and Beta Cell Technology platforms. Such research and development work will concentrate in the areas of receptor targeting, tissue hypoxia targeting, transcriptional targeting, tumor apoptosis targeting, gene expression targeting, enzymatic targeting, internal radiotherapy and local regional radio/chemotherapy. The versatility and stability of EC Technology will provide significant opportunities to create new imaging agents and therapeutic radiopharmaceuticals. In-Situ Hydrogel will provide a high-yield therapeutic delivery system that will be capable of the in-situ treatment of inoperable and unresectable tumors. N4 Technology is a very stable lipophilic technology that is being used to develop new therapeutic approaches for Alzheimer's, Parkinson's, Huntington's disease, and neuroendocrine tumors. The technology is also being used to develop new diagnostic imaging agents for use with PET cameras. Dual Agent Technology is facilitating the development of different combination agents for use with the new dual modality cameras such as SPECT/CT and PET/CT. The technology is also very adaptable for the development of radio/contrast marker agents for use with SPECT/MRI and PET/MRI cameras. One of the attributes of Dual Agent Technology will be in the ability to develop targeted radio/chemotherapy agents. The most recently acquired technology, Beta Cell Technology, will be used to develop a new diagnostic imaging agent for the early detection of pancreatic cancer. The company also plans to develop a therapeutic agent from Beta Cell Technology for use in the treatment of pancreatic cancer.

Top